Key information

🔎 Fund Overview

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.